创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: iHuPBMC-B Mouse Model

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-09 13:45
  • Views:

(Summary description)With the further development of biomedical research, scientists have an increasing need for experimental models. In recent years, InnoModels Biotechnology has developed the iHuPBMC-B mouse model, an innovative model that has shown great potential and application value in biomedical research.

InnoModels Biotechnology: iHuPBMC-B Mouse Model

(Summary description)With the further development of biomedical research, scientists have an increasing need for experimental models. In recent years, InnoModels Biotechnology has developed the iHuPBMC-B mouse model, an innovative model that has shown great potential and application value in biomedical research.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-09 13:45
  • Views:
Information

With the further development of biomedical research, scientists have an increasing need for experimental models. In recent years, InnoModels Biotechnology has developed the iHuPBMC-B mouse model, an innovative model that has shown great potential and application value in biomedical research.
The core of the iHuPBMC-B mouse model is its unique source of B lymphocytes. The model utilizes advanced cell culture and expansion techniques to efficiently obtain B lymphocytes from human Peripheral Blood Mononuclear Cells (PBMCs). This technique ensures that the resulting B lymphocytes have a high degree of activity and functional integrity, thus guaranteeing reliable and reproducible experimental results.
B lymphocytes play a crucial role in the human immune system, where they are responsible for producing antibodies against foreign pathogens. By introducing human-derived B lymphocytes into the mouse model, scientists can more accurately mimic the response of the human immune system, leading to a better understanding of the process of disease onset and progression.

 


The iHuPBMC-B mouse model has a wide range of applications and can be used in a variety of fields including in vitro experiments, drug screening, and disease modeling studies. During drug development, the model can help scientists more accurately assess the effects of drugs on the immune system, thus improving the success and efficiency of drug development. In disease modeling research, the iHuPBMC-B mouse model can simulate the occurrence and development of certain autoimmune and infectious diseases, providing new ideas and methods for disease treatment and prevention.
In addition, the iHuPBMC-B mouse model has the advantage of personalized service. Researchers can customize the personalized model according to the specific needs of the experiment, so as to better meet the experimental needs. This personalized service enables researchers to carry out experimental work more flexibly and efficiently, promoting the progress of biomedical research.
In conclusion, InnoModels' iHuPBMC-B mouse model is a revolutionary biomedical research tool. It utilizes advanced cell culture and expansion techniques to introduce human-derived B lymphocytes, providing researchers with a more accurate and reliable experimental model. This model has a wide range of applications and can be used in a variety of fields such as drug discovery and development, disease modeling research, etc., making an important contribution to the advancement of biomedical research. In the future, with the continuous development and improvement of the technology, the iHuPBMC-B mouse model is expected to show its unique advantages and value in more fields.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司